Perception de l'impact de la migraine par le patient: les outils de mesure.
Saved in:
| Title: | Perception de l'impact de la migraine par le patient: les outils de mesure. (French). |
|---|---|
| Alternate Title: | Tools for assessing patient perception of the impact of migraine. (English) |
| Authors: | El Hasnaoui, Abdelkader, Doble, Adam, Gaudin, Anne-Françoise |
| Source: | CNS Drugs. 2006 Supplement, Vol. 20, p24-36. 13p. 4 Diagrams, 7 Charts, 6 Graphs. |
| Subjects: | Migraine, Preventive medicine, Medical care, Headache, Questionnaires, Quality of life |
| Abstract (English): | Patient-reported outcome, relating to the impact of disease and therapy on the well-being of the patient, has become an essential part of medicine, guiding enlightened public health policy and resource attribution. Assessment of patient-reported outcome requires the development of specific and validated instruments, generally questionnaires completed by the patient. In the case of migraine, a number of such specific instruments have been developed to measure severity, associated disability, effects on quality of life and overall impact of headache. In addition, generic quality of life measures have allowed migraine to be compared with other pathologies. For example, using the SF-36 generic health-related quality of life profile, quality of life has been shown to be negatively associated with headache severity, impacted more by migraine headaches than by other forms of episodic headache, and diminished to a similar degree in migraine and in other chronic disorders such as depression. Migraine-specific quality of life measures have also been developed, and these are more sensitive to change than generic measures. An example is the QVM scale that has been used to demonstrate an improvement in quality of life following treatment with a triptan. Moreover, quality of life scores on this measure are inversely related to the economic cost of migraine Disability associated with migraine can be measured using the MIDAS scale. Disability has been shown to be determined by the frequency and severity of headaches and by the headache syndrome itself, with migraine causing more disability than other forms of episodic headache. The MIDAS scale has been used to develop treatment strategies stratified on the level of disability. The severity of individual headaches can be quantified using the MIGSEV scale. The severity of individual headaches has been shown to be closely associated with overall disability, quality of life and overall healthcare expenditure. Finally, the global impact of headaches is measured using the HIT-6 questionnaire, which discriminates well between different headache types and is again closely related to quality of life. These and other measures of the patient's perception of migraine have allowed an ever more precise picture of this multifacetted disorder to be drawn. [ABSTRACT FROM AUTHOR] |
| Abstract (French): | L'évaluation de l'importance d'une pathologie et de l'apport des différents traitements doit de plus en plus tenir compte de son retentissement sur le vécu subjectif du patient. Ceci implique le développement d'outils spécifiques, généralement des questionnaires auto-administrés. En ce qui concerne le retentissement de la migraine, plusieurs outils ont été proposés, visant le degré d'incapacité (par ex., échelle MIDAS), la qualité de vie (par ex., échelle QVM), la sévérité de la crise (par ex., échelle MIGSEV) et l'impact indifférencié ou global (par ex., échelle HIT- 6). Bien qu'explorant différentes composantes de la maladie, ces mesures sont en général bien corrélées entre elles. En outre, des mesures génériques de qualité de vie montrent que le retentissement de la migraine est comparable à celui d'autres pathologies chroniques. L'échelle MIDAS a été proposée comme élément discriminant d'une stratégie de soins stratifiée. Des scores correspondant à un retentissement important sur certaines de ces mesures sont associés à des dépenses de santé importantes. L'utilisation de tels outils a permis de dresser un portrait plus détaillé du retentissement de la migraine sur le vécu du patient. [ABSTRACT FROM AUTHOR] |
| Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 21638994 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Perception de l'impact de la migraine par le patient: les outils de mesure. <i>(French). </i> – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Tools for assessing patient perception of the impact of migraine.<i> (English)</i> – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22El+Hasnaoui%2C+Abdelkader%22">El Hasnaoui, Abdelkader</searchLink><br /><searchLink fieldCode="AR" term="%22Doble%2C+Adam%22">Doble, Adam</searchLink><br /><searchLink fieldCode="AR" term="%22Gaudin%2C+Anne-Françoise%22">Gaudin, Anne-Françoise</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. 2006 Supplement, Vol. 20, p24-36. 13p. 4 Diagrams, 7 Charts, 6 Graphs. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Migraine%22">Migraine</searchLink><br /><searchLink fieldCode="DE" term="%22Preventive+medicine%22">Preventive medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care%22">Medical care</searchLink><br /><searchLink fieldCode="DE" term="%22Headache%22">Headache</searchLink><br /><searchLink fieldCode="DE" term="%22Questionnaires%22">Questionnaires</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Patient-reported outcome, relating to the impact of disease and therapy on the well-being of the patient, has become an essential part of medicine, guiding enlightened public health policy and resource attribution. Assessment of patient-reported outcome requires the development of specific and validated instruments, generally questionnaires completed by the patient. In the case of migraine, a number of such specific instruments have been developed to measure severity, associated disability, effects on quality of life and overall impact of headache. In addition, generic quality of life measures have allowed migraine to be compared with other pathologies. For example, using the SF-36 generic health-related quality of life profile, quality of life has been shown to be negatively associated with headache severity, impacted more by migraine headaches than by other forms of episodic headache, and diminished to a similar degree in migraine and in other chronic disorders such as depression. Migraine-specific quality of life measures have also been developed, and these are more sensitive to change than generic measures. An example is the QVM scale that has been used to demonstrate an improvement in quality of life following treatment with a triptan. Moreover, quality of life scores on this measure are inversely related to the economic cost of migraine Disability associated with migraine can be measured using the MIDAS scale. Disability has been shown to be determined by the frequency and severity of headaches and by the headache syndrome itself, with migraine causing more disability than other forms of episodic headache. The MIDAS scale has been used to develop treatment strategies stratified on the level of disability. The severity of individual headaches can be quantified using the MIGSEV scale. The severity of individual headaches has been shown to be closely associated with overall disability, quality of life and overall healthcare expenditure. Finally, the global impact of headaches is measured using the HIT-6 questionnaire, which discriminates well between different headache types and is again closely related to quality of life. These and other measures of the patient's perception of migraine have allowed an ever more precise picture of this multifacetted disorder to be drawn. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (French) Group: Ab Data: L'évaluation de l'importance d'une pathologie et de l'apport des différents traitements doit de plus en plus tenir compte de son retentissement sur le vécu subjectif du patient. Ceci implique le développement d'outils spécifiques, généralement des questionnaires auto-administrés. En ce qui concerne le retentissement de la migraine, plusieurs outils ont été proposés, visant le degré d'incapacité (par ex., échelle MIDAS), la qualité de vie (par ex., échelle QVM), la sévérité de la crise (par ex., échelle MIGSEV) et l'impact indifférencié ou global (par ex., échelle HIT- 6). Bien qu'explorant différentes composantes de la maladie, ces mesures sont en général bien corrélées entre elles. En outre, des mesures génériques de qualité de vie montrent que le retentissement de la migraine est comparable à celui d'autres pathologies chroniques. L'échelle MIDAS a été proposée comme élément discriminant d'une stratégie de soins stratifiée. Des scores correspondant à un retentissement important sur certaines de ces mesures sont associés à des dépenses de santé importantes. L'utilisation de tels outils a permis de dresser un portrait plus détaillé du retentissement de la migraine sur le vécu du patient. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=21638994 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2165/00023210-200620001-00005 Languages: – Code: fre Text: French PhysicalDescription: Pagination: PageCount: 13 StartPage: 24 Subjects: – SubjectFull: Migraine Type: general – SubjectFull: Preventive medicine Type: general – SubjectFull: Medical care Type: general – SubjectFull: Headache Type: general – SubjectFull: Questionnaires Type: general – SubjectFull: Quality of life Type: general Titles: – TitleFull: Perception de l'impact de la migraine par le patient: les outils de mesure. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: El Hasnaoui, Abdelkader – PersonEntity: Name: NameFull: Doble, Adam – PersonEntity: Name: NameFull: Gaudin, Anne-Françoise IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 01 Text: 2006 Supplement Type: published Y: 2006 Identifiers: – Type: issn-print Value: 11727047 Numbering: – Type: volume Value: 20 Titles: – TitleFull: CNS Drugs Type: main |
| ResultId | 1 |
